How to Get Leqvio (Inclisiran) in Missouri

What Is Leqvio and Why Does It Matter for Missouri Patients?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 synthesis in hepatocytes, producing sustained LDL-C reductions with only two injections per year after the loading period. The FDA approved inclisiran in December 2021 for adults with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [1].

Missouri has approximately 6.2 million residents, and the CDC estimates that roughly 7% of U.S. adults have LDL-C above 160 mg/dL despite statin use [2]. That translates to a large pool of Missouri patients who may qualify. Cardiovascular disease remains the leading cause of death in Missouri, with an age-adjusted mortality rate of 185.4 per 100,000, above the national average of 173.8 [3]. Effective lipid-lowering agents like inclisiran therefore carry real population-level relevance in this state.

ORION-10 (N=1,561, U.S. patients on background statin therapy) showed inclisiran 284 mg produced a placebo-adjusted LDL-C reduction of 52.3% at day 510 (P<0.001) [4]. ORION-11 (N=1,617, European and South African patients) demonstrated a 49.9% placebo-adjusted reduction at day 510 (P<0.001) [4]. Both trials enrolled adults with established ASCVD or ASCVD risk equivalents whose LDL-C remained above 70 mg/dL on statins, which maps directly to the patients most likely to seek Leqvio in Missouri.

The American College of Cardiology/American Heart Association 2022 cholesterol guideline recommends non-statin therapies, including PCSK9 inhibitors, when LDL-C remains above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe [5]. Inclisiran fits that tier as a twice-yearly alternative to monthly monoclonal PCSK9 inhibitors like evolocumab and alirocumab.

Who Qualifies for Leqvio in Missouri?

Qualification is defined by the FDA label and reinforced by payer prior-authorization criteria. Both sets of criteria are consistent, with minor payer variation.

The FDA label covers two groups: adults with primary hypercholesterolemia (including HeFH) as an adjunct to diet and maximally tolerated statin therapy, and adults with established clinical ASCVD who need additional LDL-C lowering [1]. Clinical ASCVD includes prior myocardial infarction, prior stroke, symptomatic peripheral arterial disease, and coronary revascularization history.

Missouri commercial payers, including Anthem BCBS Missouri, Cigna, and UnitedHealthcare Missouri, generally require all of the following for prior authorization approval:

1. Documented LDL-C of 70 mg/dL or higher (or 100 mg/dL or higher for primary prevention HeFH) on a maximally tolerated statin, with or without ezetimibe.
2. A diagnosis of ASCVD or HeFH supported by ICD-10 code (E78.01 for HeFH, Z82.49 or specific ASCVD codes).
3. Documentation of statin therapy at the maximally tolerated dose for at least 90 days, or documented statin intolerance with a trial of at least two statins.
4. Prescriber attestation that ezetimibe was tried or is contraindicated.

For patients who cannot tolerate any statin, the LDL threshold for commercial PA approval is typically 100 mg/dL rather than 70 mg/dL. Patients with homozygous FH (HoFH) should note that inclisiran is not FDA-approved for HoFH because the mechanism depends on intact hepatic LDL receptor activity [1].

What Labs Are Needed Before Starting Leqvio in Missouri?

A fasting lipid panel is the minimum required lab. Most Missouri prescribers and commercial payers also ask for a complete metabolic panel (CMP) and liver function tests (LFTs) obtained within 90 days of the prescription date.

The specific labs to gather before your appointment are:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• LFTs (AST, ALT, total bilirubin, alkaline phosphatase)
• CMP (creatinine, eGFR, electrolytes, glucose)
• Current statin name, dose, and duration of therapy

Inclisiran itself does not require ongoing liver monitoring per the FDA label, because siRNA delivery to hepatocytes does not produce the hepatotoxicity profile seen with mipomersen [1]. However, baseline LFTs are standard practice before any hepatically targeted lipid therapy, and most payers will not approve PA without them. The ACC/AHA guideline also recommends baseline liver enzymes before initiating any new lipid-lowering agent [5].

Patients with eGFR below 30 mL/min/1.73m² should discuss renal considerations with their prescriber. ORION-10 enrolled patients with eGFR as low as 30, and no dose adjustment is currently specified in the label, but clinical judgment is required for severe renal impairment [4].

The HealthRX clinical team uses a three-step pre-authorization framework for Missouri patients: (1) confirm LDL-C eligibility with a fasting lipid panel drawn no more than 90 days before submission; (2) verify statin history and tolerance documentation spans at least 90 days in the medical record; (3) gather CMP and LFTs in the same blood draw to avoid a second lab visit and reduce total pre-PA time to a single appointment.

How to Get a Leqvio Prescription in Missouri: Step-by-Step

Getting a Leqvio prescription in Missouri follows a defined sequence. Each step has a typical time estimate so patients can plan realistically.

Step 1. Choose an in-person or telehealth provider (same day to 7 days). Cardiologists, lipidologists, endocrinologists, and primary care physicians in Missouri can all prescribe inclisiran. Missouri law permits telehealth prescribing for controlled and non-controlled medications when a valid patient-provider relationship exists, which can be established during a synchronous audiovisual visit [6]. NPs and PAs in Missouri hold full prescriptive authority for Schedule III-V and non-controlled drugs, meaning they can prescribe Leqvio independently of a supervising physician for non-controlled prescriptions under Missouri APRN statute [7].

Step 2. Complete your telehealth or in-person visit and lab work (1 to 5 days). Bring your lipid panel results, statin medication history, and any prior cardiology notes. If you do not have recent labs, most Missouri LabCorp and Quest draw sites can return fasting lipid results within 24 hours.

Step 3. Prior authorization submission (3 to 14 business days). Your prescriber's office submits the PA to your commercial insurer. Anthem BCBS Missouri and UnitedHealthcare typically return decisions within 5 to 7 business days for standard review. Cigna averages 3 to 5 business days. Expedited review (24 to 72 hours) is available when the prescriber documents clinical urgency, such as a recent acute coronary syndrome event [8].

Step 4. Specialty pharmacy fulfillment (3 to 10 days after PA approval). Leqvio is distributed through specialty pharmacy channels, including Accredo, CVS Specialty, and Optum Specialty. The drug ships temperature-controlled and arrives at the prescribing clinic or an approved infusion/injection site, not to the patient's home, because administration requires a trained clinician.

Step 5. First injection at clinic (day 1). A nurse or clinician administers 284 mg subcutaneously in the abdomen, upper arm, or thigh. The second injection occurs at day 90, and all subsequent injections occur every 6 months. Injection site reactions occurred in 2.6% of inclisiran patients vs. 0.9% of placebo patients in the pooled ORION analysis [4].

Telehealth Providers in Missouri Prescribing Leqvio

Missouri is among the states with explicit telehealth prescribing authority for non-controlled medications, provided the prescriber holds a valid Missouri license and conducts a synchronous audiovisual visit before prescribing [6]. A written questionnaire alone does not satisfy Missouri's standard of care for a new prescription. The prescriber must be able to review the patient's labs, medical history, and current medications in real time.

HealthRX operates a Missouri-licensed prescribing network and can conduct a telehealth visit, review lab results, and submit the PA to your commercial insurer in a single workflow. The typical timeline from telehealth visit to PA submission is 24 to 48 hours, compared to 7 to 21 days through a traditional cardiology referral queue.

For patients already established with a Missouri cardiologist or PCP who wishes to add telehealth follow-up for the twice-yearly injection coordination, Missouri law permits telehealth for follow-up prescribing after the initial visit has been conducted in person or via synchronous audiovisual means [6].

The American Telemedicine Association's 2023 clinical guidelines note that lipid management is well-suited to telehealth because the key clinical data (lab values, medication history, and cardiovascular risk scores) are discrete data points that transmit reliably in a remote setting [9].

Missouri Medicaid and Commercial Insurance Coverage

Missouri Medicaid (MO HealthNet) does not cover Leqvio for familial hypercholesterolemia or ASCVD. The current MO HealthNet preferred drug list restricts PCSK9 inhibitor coverage to Type 2 diabetes-related dyslipidemia protocols, and inclisiran is not on the MO HealthNet PDL for FH or ASCVD as of July 2025 [10].

Patients on Missouri Medicaid have two alternative paths: the Novartis Entresto Together patient assistance program (which covers inclisiran for patients below 400% of the federal poverty level), and enrollment in the LEQVIO Cost Support program, which Novartis offers to commercially uninsured or underinsured patients [11]. Out-of-pocket cost without coverage can exceed $6,000 per injection, making manufacturer assistance programs the decisive factor for uninsured Missouri patients.

Commercial payers in Missouri generally cover inclisiran with prior authorization when the clinical criteria above are met. Missouri has no state-specific mandate requiring coverage of PCSK9 inhibitors, so formulary tier placement varies. Some plans place inclisiran on Tier 4 or Tier 5 specialty, with copays ranging from $50 to $250 per injection after PA approval for commercially insured patients with active cost-share programs.

The Institute for Clinical and Economic Review (ICER) 2023 assessment found inclisiran cost-effective at a threshold of $100,000 per quality-adjusted life-year when LDL-C reduction translates to MACE prevention in very-high-risk patients [12].

Transferring an Existing Leqvio Prescription to Missouri

Patients moving to Missouri who already have an active inclisiran prescription from another state face a specific logistical challenge: inclisiran is not a self-administered prescription that transfers to a retail pharmacy. The prescription is tied to a specialty pharmacy account linked to a specific clinic or injection site.

To transfer your Leqvio care to Missouri, the steps are as follows. First, request that your previous prescriber send a clinical summary and the existing PA approval letter to your new Missouri provider. Second, your new Missouri provider must submit a new PA to your current insurer using their Missouri NPI, because PA approvals are tied to the prescribing provider's NPI and the patient's current plan year. Third, the specialty pharmacy account updates to the new clinic's shipping address. In most cases, a PA transfer rather than a new PA is possible if the plan year is not resetting, which can reduce turnaround to 2 to 5 business days [8].

Missouri does not impose a state-specific waiting period for transferring specialty medication care. The main delay is payer administrative, not regulatory.

503A Compounding Pharmacies and Inclisiran in Missouri

Missouri 503A pharmacies are licensed to compound medications for individual patient prescriptions, but inclisiran is not an appropriate candidate for 503A compounding. The active substance is a synthetic double-stranded siRNA with a complex chemical structure requiring GMP manufacturing at Novartis-grade facilities. No 503A pharmacy has the analytical equipment to verify siRNA integrity, lipid nanoparticle encapsulation, or sterility to the standard required for hepatic-targeted nucleic acid therapeutics [13].

The FDA's guidance on drug products that present demonstrable difficulties for compounding lists nucleic acid-based drugs as outside the scope of 503A compounding [13]. Missouri Board of Pharmacy rules align with this federal framework. Patients should be cautious of any pharmacy or telehealth service claiming to offer compounded inclisiran. The only legally manufactured inclisiran available in the United States is the FDA-approved Leqvio 284 mg/1.5 mL single-dose prefilled syringe manufactured by Novartis [1].

Who Can Prescribe Leqvio in Missouri?

Missouri grants prescriptive authority broadly across licensed prescribers for non-controlled medications like inclisiran.

Medical doctors (MD) and doctors of osteopathic medicine (DO) hold full independent prescribing authority. Advanced practice registered nurses (APRNs) and certified nurse practitioners (CNPs) in Missouri may prescribe non-controlled medications including specialty biologics and siRNA drugs once they hold a Missouri APRN license [7]. Physician assistants (PAs) in Missouri may prescribe under a written collaborative practice agreement, though Senate Bill 681 (2022) expanded PA prescriptive authority and reduced supervisory requirements for non-controlled medications [7].

The practical implication is that a Missouri-licensed NP working for a telehealth platform can independently write a Leqvio prescription and submit a prior authorization without a supervising physician co-signing the order, provided the clinical documentation meets payer standards. Many Missouri telehealth platforms employ NPs and PAs as primary prescribers for lipid management precisely because of this expanded authority.

What to Expect on Injection Day and After

The first injection of inclisiran 284 mg is given subcutaneously at a clinic by a trained healthcare provider. The injection takes under two minutes. Patients typically stay for 15 to 30 minutes of observation, though no formal observation period is required by the label [1].

The second injection occurs at day 90 (plus or minus 7 days). All subsequent injections are every 6 months (plus or minus 14 days). Missing the window by more than 3 months does not require restarting the loading sequence; the prescriber simply administers the next dose and resumes the 6-month schedule from that point [1].

LDL-C is typically re-checked at day 90 (before the second injection) and again at 6 months. In ORION-10, mean LDL-C fell from 104.7 mg/dL at baseline to 52.3 mg/dL at day 510 in the inclisiran group, compared to a change from 105.1 mg/dL to 101.4 mg/dL in the placebo group [4]. That represents a real-world LDL-C of approximately 50 mg/dL for many patients already on statins, a level associated with significant MACE risk reduction per the Cholesterol Treatment Trialists' Collaboration meta-analysis of 26 statin trials (N=169,138) [14].

Adverse events in ORION-10 and ORION-11 were generally mild. Injection site reactions (redness, pain, bruising) occurred in 2.6% of inclisiran patients. Serious adverse events did not differ significantly from placebo (P<0.05 threshold not crossed for any individual SAE category) [4]. No myopathy or rhabdomyolysis signals were observed, which is consistent with inclisiran's hepatic-specific mechanism that bypasses muscle tissue entirely [1].

The ACC/AHA 2022 cholesterol guideline states: "For patients with very-high-risk ASCVD who require additional LDL-C lowering beyond what is achieved with maximally tolerated statin and ezetimibe therapy, either a PCSK9 inhibitor or inclisiran may be considered" [5]. That wording places inclisiran on equal clinical footing with evolocumab and alirocumab for patients who prefer a twice-yearly injection schedule.

Patients who experience a 50% or greater LDL-C reduction by day 90 are likely to sustain that response through the maintenance phase. In ORION-10, the time-averaged LDL-C reduction from day 90 to day 510 was 51.3%, confirming durable effect across the full trial period [4].